The Host Cell Protein Testing Market Size was valued at USD 1.33 billion in 2023 and is expected to reach USD 2.11 billion by 2031 and grow at a CAGR of 5.93% over the forecast period 2024-2031.
Host Cell Proteins are low-level protein impurities identified in therapeutic products obtained from the host organism during bio therapeutic production (HCPs). Many endogenous proteins can be produced by host cell systems during the production of a re combinant protein medication. Re combinant proteins, particularly monoclonal antibodies, offer potentially novel therapy approaches for previously incurable diseases. As a result, their importance in the pharmaceutical sector is rapidly growing. To create re combinant proteins for therapeutics, insect cells, yeast, and bacteria are used as expression hosts.
Get more information on Host Cell Protein Testing Market - Request Sample Report
HCPs, the most frequent type of process-related impurity, are undesirable in pure protein products because they may endanger human safety. HCPs may be biologically active in the human body, or they may destroy the therapeutic protein or product-stabilizing chemicals, affecting product stability.
KEY DRIVERS:
The growing demand for medications to treat various types of cancer and inflammatory disorders has compelled market participants to upgrade biopharmaceutical research and production facilities.
Biopharmaceutical advancements with expanding R&D activity
RESTRAINTS:
Concerns Regarding Immunogenesis
Problems With The Efficiency And Accuracy Of The Test Kits
OPPORTUNITY:
Automated mass spectrometry is being used to detect host cell proteins.
The industry is investing in technologies that will allow the detection of host cell protein in commercially generated antibodies to be automated.
The global spread of the fatal corona virus has hampered the movement of commodities across continents and regions. The virus outbreak impacted the entire supply chain, from raw material delivery to finished goods transit. The providers have formed a special team to assess the complete supply chain of raw materials and finished goods. During the pandemic era, the special team is responsible for assessing cross-border problems and trade restrictions. Furthermore, in order to meet the criteria, the manufacturers have improved their transportation facilities and upgraded their packaging infrastructure.
Assays based on polymerase chain reaction (PCR) are used to detect genetic material from a specific organism, such as a virus. These assays are generally used for the rapid and precise diagnosis of infectious disorders caused by viruses or bacteria. It is also utilised to identify on-cultivable or slow-growing microorganisms from tissue culture assays and animal models, such as anaerobic bacteria, mycobacteria, or viruses. It enables the detection of small numbers of disease organisms in convenient samples, whether dead or alive. Standard single PCR, allele-specific PCR, multiplex PCR, and real-time PCR are all examples of PCR-based assays.
The ELISA-based assay is a plate-based assay technique for detecting and quantifying soluble molecules such proteins, peptides, hormones, and antibodies. Direct ELISA, indirect ELISA, sandwich ELISA, and competitive ELISA are the four types of ELISA. An antigen-coated multi-well plate is detected by an antibody that has been directly coupled to an enzyme in the direct ELISA experiment. It is a fast detection method that eliminates secondary antibody cross-reactivity. Sandwich ELISA is a form of enzyme-linked immunosorbent test that employs two antibodies, one for detection and one for capture. It offers several benefits, including high specificity, adaptability for complicated samples, versatility, and sensitivity. A surface/plate-based test, competitive ELISA coats the plate with capture antibodies reactive to the chemical of interest. A competitive ELISA assay requires no sample preparation and can employ crude or impure samples.
A mass spectrometry-based test has evolved as an effective analytical technique for identifying, characterising, and quantifying different macromolecules in biological materials. In recent years, quantitative bioanalysis of proteins has gained increasing attention and interest. It has several advantages, including the capacity to assess numerous analytes in a single analytical run, the ease with which new assays may be developed, minimal volume requirements, and inexpensive reagent costs. In medication development, there is an increasing demand for quantitative bioanalysis of protein therapies.
Contract research groups want to evaluate host cell proteins. A contract research organisation (CRO) is a corporation that provides outsourced pharmaceutical research services to pharmaceutical and biotechnology companies. In 2021, there will be 4,087 contract research organisations enterprises in the United States, according to IBIS World. Contract research organisations employ host cell protein testing for researching novel treatments and pharmaceuticals. It aids in the development of biological assays, preclinical research, and the administration of clinical trials. It aids in the progression of new pharmaceuticals from conception to FDA/EMA marketing approval.
Biopharmaceutical businesses use host cell protein testing. Biopharmaceutical medications are used to treat a wide range of disorders, including cardiovascular disease, diabetes, and cancer. Mammalian cell lines, microbial cells, and plant cell cultures can all be used to make it. Biopharmaceuticals such as recombinant proteins and therapeutic antibodies are created in host cells that have been genetically modified. To assure product safety, host cell protein testing effectively removes host cell contaminants from production cell lines.
by End User
CROs
Biopharmaceutical Companies
by Type
PCR-based Assays
ELISA-based Assays
.png)
Need any customization research on Host Cell Protein Testing Market - Enquiry Now
North America dominated the global host cell protein testing market due to a variety of factors, including advancements in the biopharmaceutical sectors, increased investment in R&D activities, and the region's well-established healthcare infrastructure. North America is separated into two countries: the United States and Canada. The United States is the world leader in biopharmaceutical R&D and the largest biopharmaceutical market, increasing demand for host cell protein testing solutions in the region. For more than 30 years, the biopharmaceutical industry in the United States has been the global leader in the development of novel medications. Furthermore, market leaders' collaboration and alliances are projected to result in highly innovative, industry-leading solutions, fuelling demand for host cell protein testing across the region. Canada also boasts a large number of biotechnology firms.
Europe has also emerged as a significant market for host cell protein testing, with well-established R&D facilities throughout the area, the availability of supportive regulatory regimes, and companies developing new and cost-effective host cell protein testing solutions. The United Kingdom boasts a one-of-a-kind global health and life sciences ecosystem, as well as a solid track record of scientific discoveries with next-generation technology and services. The government provides an R&D platform for market enterprises. Government initiatives and research funding are also propelling this business forward.
Because of the presence of a large target population suffering from chronic diseases such as cancer, increased government investment in healthcare infrastructure, and increased awareness about chronic diseases, Asia Pacific presents lucrative opportunities for players operating in the host cell protein testing market. Cancer cases in India could rise by 12% in the next five years, according to the Indian Council of Medical Research (ICMR) and the National Centre for Disease Informatics and Research (NCDIR). The governments are conducting numerous programme to raise public awareness.
In India, the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) was introduced with the goals of eliminating regional inequalities in the availability of affordable/reliable tertiary healthcare services and expanding facilities for quality medical education.
REGIONAL COVERAGE:
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Major players are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Cygnus Technologies, Llc, Biogenes Gmbh, Cisbio Bioassays, Charles River Laboratories International, Inc., Rockland Immunochemicals, Inc. and Abcam Plc, Cytiva, Enzo Life Sciences, Inc. and other players.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 1.33 Billion |
| Market Size by 2031 | US$ 2.11 Billion |
| CAGR | CAGR of 5.93% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • by End User (CROs, Biopharmaceutical Companies) • by Type (PCR-based Assays, ELISA-based Assays) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Cygnus Technologies, Llc, Biogenes Gmbh, Cisbio Bioassays, Charles River Laboratories International, Inc., Rockland Immunochemicals, Inc. and Abcam Plc, Cytiva, Enzo Life Sciences, Inc. |
| Key Drivers | • Biopharmaceutical advancements with expanding R&D activity. |
| RESTRAINTS | • Concerns Regarding Immunogenesis • PROBLEMS WITH THE EFFICIENCY AND ACCURACY OF THE TEST KITS |
Ans: The Host Cell Protein Testing Market Expected to reach USD 1.99 billion by 2030.
Ans: The host Cell Protein Testing Market grow at a CAGR of 5.81% over the forecast period 2023-2030.
Ans: Host Cell Proteins are low-level protein impurities identified in therapeutic products obtained from the host organism during biotherapeutic production (HCPs).
Ans: The major players are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Cygnus Technologies, Llc, Biogenes Gmbh, Cisbio Bioassays, Charles River Laboratories International, Inc., Rockland Immunochemical, Inc. and Abcam Plc, Cytiva, Enzo Life Sciences, Inc., and others in final report.
The growing demand for medications to treat various types of cancer and inflammatory disorders has compelled market participants to upgrade biopharmaceutical research and production facilities.
Biopharmaceutical advancements with expanding R&D activity
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.1 Introduction
4.3.2 Impact on major economies
4.3.2.1 US
4.3.2.2 Canada
4.3.2.3 Germany
4.3.2.4 France
4.3.2.5 United Kingdom
4.3.2.6 China
4.3.2.7 Japan
4.3.2.8 South Korea
4.3.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Host Cell Protein Testing Market, by End User
8.1 CROs
8.2 Biopharmaceutical Companies
9. Host Cell Protein Testing Market, by Type
9.1 PCR-based Assays
9.2 ELISA-based Assays
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 USA
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Italy
10.3.5 Spain
10.3.6 The Netherlands
10.3.7 Rest of Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 South Korea
10.4.3 China
10.4.4 India
10.4.5 Australia
10.4.6 Rest of Asia-Pacific
10.5 The Middle East & Africa
10.5.1 Israel
10.5.2 UAE
10.5.3 South Africa
10.5.4 Rest
10.6 Latin America
10.6.1 Brazil
10.6.2 Argentina
10.6.3 Rest of Latin America
11. Company Profiles
11.1 Thermo Fisher Scientific Inc.
11.1.1 Financial
11.1.2 Products/ Services Offered
11.1.3 SWOT Analysis
11.1.4 The SNS view
11.2 Bio-Rad Laboratories, Inc.
11.3 Cygnus Technologies, Llc
11.4 Biogenes Gmbh
11.5 Cisbio Bioassays
11.6 Charles River Laboratories International, Inc.
11.7 Rockland Immunochemicals, Inc.
11.8 Abcam Plc
11.9 Cytiva,
11.10 Enzo Life Sciences, Inc.
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Medical Aesthetics Market size was valued at USD 13.5 billion and is estimated to be USD 32.49 billion and grow at a compound annual growth rate of approx. CAGR of 11.6% for the forecast period of 2024-2031.
The Patient Flow Management Solutions Market Size was valued at USD 18.86 billion in 2022, and expected to reach USD 67.16 billion by 2030, and grow at a CAGR of 17.2% over the forecast period 2023-2030.
The Digital PCR-dPCR Market size was valued at US$ 419.25 Million in 2022 and is projected to reach US$ 2196.40 Million by 2030, with a growing CAGR of 23% during the forecast period 2023-2030.
The Life Science Tools Market size was estimated USD 145.01 billion in 2022 and is expected to reach USD 331.7 billion by 2030 at a CAGR of 10.9% during the forecast period of 2023-2030.
The Drug Eluting Stent Market size was estimated USD 2897.6 million in 2022 and is expected to reach USD 4795.51million by 2030 at a CAGR of 6.5% during the forecast period of 2023-2030.
The Pharmacovigilance and Drug Safety Software Market Size was valued at USD 6.83 billion in 2022, and is expected to reach USD 14.86 billion by 2030, and grow at a CAGR of 10.2% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
